Catalyst Event
Amgen Inc (AMGN) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
6/1/2026, 12:00:00 AM
European Commission granted marketing authorization for IMDYLLTRA (tarlatamab) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. High importance due to major drug approval potential, expected.
Korean Translation
유럽연합 집행위원회로부터 백금 기반 화학요법 이후 질병이 진행된 성인 확장병기 소세포폐암(ES-SCLC) 환자 치료를 위한 임딜트라(타르라타맙)의 판매 허가를 승인받음. 신약 승인에 따른 매출 증대 기대감으로 높은 중요도로 분류함, 예상됨.
Related Recent Events
Life Time Group Holdings Inc (LTH) · Earnings Release
Q2 2026 earnings release on 2026-08-04 with analyst EPS forecast of $0.43; low importance estimated due to no current market impact, expected.
8/4/2026, 12:00:00 AM
Novartis AG (NVS) · Earnings Release
Second quarter 2026 financial results for 2026-07-21; low importance estimated as the date is a routine reporting event with an expected impact of approximately 1% scheduled.
7/21/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.
6/19/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
Quarterly dividend of $0.85 per share has an ex-dividend date of June 15, 2026, scheduled.
6/15/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Ex-dividend date for a quarterly cash dividend of $1.25 per share on 2026-06-12. The dividend was declared on May 26, 2026, and is payable on June 26, 2026. A price impact of approximately 1% is expected based on the dividend amount.
6/12/2026, 12:00:00 AM